Compare LAW & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAW | NGNE |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.2M | 327.8M |
| IPO Year | 2021 | N/A |
| Metric | LAW | NGNE |
|---|---|---|
| Price | $8.19 | $21.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $7.75 | ★ $38.50 |
| AVG Volume (30 Days) | ★ 283.2K | 207.7K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $152,677,000.00 | N/A |
| Revenue This Year | $8.51 | N/A |
| Revenue Next Year | $7.46 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.33 | N/A |
| 52 Week Low | $3.31 | $6.88 |
| 52 Week High | $9.11 | $37.27 |
| Indicator | LAW | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 59.57 | 47.23 |
| Support Level | $8.20 | $19.03 |
| Resistance Level | $8.72 | $21.97 |
| Average True Range (ATR) | 0.37 | 1.51 |
| MACD | -0.02 | 0.29 |
| Stochastic Oscillator | 57.35 | 50.24 |
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.